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Copyright © 2019 Elin Strand et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Dietary fatty acids (FAs) affect certain metabolic routes, including pathways controlled by the peroxisome proliferator-activated
receptors (PPARs), but tissue-specific effects are not well-defined.Thus, the aim was to compare the metabolic response in hepatic,
adipose, and cardiac tissues after treatment with specific PPAR agonists. Male Wistar rats were randomized into three groups: a
control group receiving placebo (n=8); a PPAR𝛼 agonist group receiving WY-14,643 (n=6); and a PPAR𝛾 agonist group receiving
rosiglitazone (n=6) for 12 days. All animals received a low-fat standard chow diet and were given a daily dose of placebo or agonist
orally. Lipids and FA methyl esters were measured in plasma, liver, and heart and gene expression was measured in liver and
adipose tissue, while enzyme activities were measured in liver. Treatment with the PPAR𝛼 agonist was associated with higher
liver mass relative to body weight (liver index), lower plasma, and hepatic total cholesterol, as well as lower plasma carnitine and
acylcarnitines, compared with control. In heart, PPAR𝛼 activation leads to overall lower levels of free FAs and specific changes in
certain FAs, compared with control. Furthermore, 𝛽-oxidation in liver and the enzymatic activities of well-known PPAR𝛼 targeted
genes were higher following PPAR𝛼 administration. Overall, rats treated with the PPAR𝛼 agonist had higher hepatic saturated FAs
(SFAs) andmonounsaturated FAs (MUFAs) and lower n-6 and n-3 PUFAs, compared to control. Treatment with the PPAR𝛾 agonist
was associated with a lower liver index, lower plasma triglycerides (TAG) and phospholipids, and higher hepatic phospholipids,
compared with control. PPAR𝛾 target genes were increased specifically in adipose tissue. Moreover, lower total cardiac FAs and SFA
and higher cardiac n-6 PUFA were also associated with PPAR𝛾 activation. Altogether, there were characteristic effects of PPAR𝛼
activation in liver and heart, as well as in plasma. PPAR𝛾 effects were not only confined to adipose tissue, but specific effects were
also seen in liver, heart, and plasma. In conclusion, short-term treatment with PPAR agonists induced tissue-specific effects on FA
composition in liver and heart. Moreover, both PPAR𝛼 and PPAR𝛾 activation lowered plasma TAG and phospholipids, most likely
through effects on liver and adipose tissue, respectively. In future studies we aim to reveal whether similar patterns can be found
through diet-induced activation of specific pathways.
1. Introduction
Peroxisome proliferator-activated receptors (PPARs) belong
to the superfamily of nuclear receptors and are central
transcription factors governing pathways involved in energy
metabolism and homeostasis [1]. PPAR𝛼 is highly expressed
inmetabolically active tissues like the liver, heart, and kidneys
and is involved in regulating genes related to glucose and lipid
metabolism [2], while PPAR𝛾 is abundantly expressed in adi-
pose tissue, where it controls lipid storage and differentiation
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of adipocytes [3]. PPAR𝛾 is also expressed in several other
tissues, and its action includes traits like improved insulin
sensitivity [4] and holds anti-inflammatory properties [5].
Since PPAR𝛼 has hypolipidemic and PPAR𝛾 has insulin
sensitizing properties, these transcription factors have been
of large clinical interest as targets for medical treatment
of conditions involving cardiovascular disease and diabetes
[6, 7]. Fatty acids (FAs) and their derivatives are natural
ligands for the PPARs, and diet will consequently have a
significant impact on their activities [8]. An increased focus
on dietary fat, including the proposed beneficial effects of
polyunsaturated FAs [9] and trend diets like the high fat-low
carbohydrate diet [10], necessitates studies on how the inter-
nal organs are affected. Well-known synthetic PPAR ligands
include fibrates activating PPAR𝛼 and thiazolidinediones
activating PPAR𝛾 [1]. Although the main metabolic effects of
PPAR𝛼 and 𝛾 have been documented in rodents and humans,
few studies have performed such comprehensive and direct
comparison of PPAR activation effects on lipid metabolism
and lipid status across important metabolic organs.
The objective of the current study was to compare how
short-term activation of PPAR𝛼 and 𝛾 affected metabolism
through lipid levels and FA composition, as well as gene
regulation in liver and adipose tissue. For this purpose, male
Wistar rats were treated for 12 days with the specific PPAR
agonists WY-14,643 (PPAR𝛼) and rosiglitazone (PPAR𝛾),
followed bymeasuring hepatic and cardiac lipids, FA compo-
sition, as well as certain hepatic and adipose genes expected
to respond to PPAR activation.
2. Methods
2.1. Animals and Study Design. The animal experiments were
standardized according to the Guidelines for the Care and
Use of Experimental Animals, and the protocol was approved
by the Norwegian Committee for Experiments on Animals,
and in accordance with the Norwegian legislation and reg-
ulations governing experiments using live animals (FOTS
ID: 2014/6187). The experiment was done in accordance with
the regulations laid down by the National Animal Research
Authority.
A total of 20 male Wistar rats, aged eight weeks (200-
225 g), were obtained from Taconic Europe A/S (Ry, Den-
mark). They were housed 2-3 animals per cage (Makrolon
IV). The animal room maintained a constant 12 h light–dark
cycle at a temperature of 22± 2∘C, a relative humidity of
55± 5%, and underwent 20 air changes per hour. Common
environmental enrichment was used. Animals were accli-
matized under these conditions for six days prior to study
start and had free access to standard chow and tap water
throughout the study. During the following two days prior to
study intervention, animals were habituated careful handling,
and they were introduced to the muffin dough to be used as
a vehicle for the PPAR agonists.
The animals were randomized into the following three
groups: (1) Placebo (control, n=8); (2) PPAR𝛼 agonist (n=6);
and (3) PPAR𝛾 agonist (n=6). Block randomization was
used when placing the animals into cages, as well as for
the terminal operation. Sample size in each group was
determined based on an assumed profound response (if any)
in the PPAR intervention groups. All animals received a
low-fat chow diet. In addition, during the 12 days of study
intervention each animal was given a daily supplement of
300 𝜇l muffin dough as a vehicle with or without agonist.
Treatments were given according to the following daily
routine: the placebo control group received pure vehicle
(without agonist); the PPAR𝛼 agonist group received vehicle
with 20mg/kg/day WY-14,643 (Tocris Bioscience, Bristol,
UK); and the PPAR𝛾 agonist group received vehicle with
10mg/kg/day rosiglitazone (Sigma-Aldrich, St. Louis, MO).
Ingredients in the muffin dough vehicle were eggs, sugar,
gluten free flour, vanilla sugar, milk, and butter. Animal
weights were measured at day 0, day 6, and day 12 during the
experiment. Feed intake was estimated by weighing the food
provided to each cage and finally weighing the residual feed
on day 12.
The animals received anesthesia with 2% isoflurane
(Schering-Plough, Kent, UK) under fasting conditions after
12 days of intervention. The abdomen was opened in the
midline and the animals were sacrificed by cardiac puncture
and exsanguination. Blood was collected in BD Vacutainer
tubes containing EDTA (Becton, Dickinson, and Company,
Plymouth, UK). Liver, heart, and epididymal adipose tissue
were collected, weighed, and snap-frozen as drainage of
blood from the animal was complete. Liver mass relative
to body weight (liver index) was calculated by the formula
[100∗(liver weight in g/body weight in g)]. A liver piece
for the 𝛽-oxidation was collected by cutting a piece of
the main lobe. A small piece was also collected for FA
analyses. Plasma and tissue samples were stored at −80∘C
until analyses.
2.2. Biochemical Analyses. Plasma, hepatic, and cardiac lipids
were measured on the Hitachi 917 system (Roche Diagnos-
tics, GmbH, Mannheim, Germany). Total cholesterol, HDL
cholesterol, LDL cholesterol, and TAG kits were from Roche
Diagnostics and the phospholipids, free cholesterol, and free
FAs kits from DiaSys Diagnostic Systems GmbH (Holzheim,
Germany). Plasma carnitine metabolites were determined
by high performance liquid chromatography-tandem mass
spectrometry (LC-MS/MS) as previously described [11–13].
FA methyl esters (FAME) were prepared from hepatic and
cardiac tissues and analyzed by gas-liquid chromatography
(GC) as previously described [14]. The anti-inflammatory
index was calculated based on the formula ((C22:6n-3 +
C22:5n-3 + C20:3n-6 + C20:5n-3) / C20:4n-6)∗10 [15].
2.3. Hepatic Enzyme Activities. Liver tissue samples were
homogenized and fractionated as previously described [16].
Thepostnuclear fractionwas used for further analyses. Liquid
scintillation with (1-14C) palmitoyl-CoA as a substrate was
used to determine𝛽-oxidation capacity in liver in the absence
and presence of malonyl-CoA [17]. The activities of carni-
tine palmitoyl transferase 2 (CPT-II) [18], fatty acyl-CoA
oxidase (ACOX) [19, 20], and 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) synthase [21] weremeasured as previously
described.
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2.4. Gene Expression Analyses. Total cellular RNA was
purified from tissue using the RNeasy kits with the RNeasy
Mini protocol for liver and the RNeasy Lipid Tissue protocol
for adipose tissue (Qiagen GmbH, Hilden, Germany). RNA
quantity was determined spectrophotometrically (NanoDrop
1000, Thermo Scientific, Wilmington, DE, USA), while
quality was evaluated by capillary electrophoresis (Agilent
2100 Bioanalyzer, Agilent Technologies Inc., Santa Clara,
CA, USA). RNA was reversely transcribed to cDNA in 20 𝜇l
reactions (containing 500mg RNA) using the High Capacity
cDNAReverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA). Samples were treated with RNase inhibitors
as part of the protocol. Selected genes were analyzed
using qPCR with the ABI PRISM 7900 HT Sequence
Detection System (Applied Biosystems): Rn00566193
(Ppar𝛼), Rn00440945 (Ppar›), Rn00580241 (Pgc1𝛼),
Rn00580702 (Cpt1a), Rn00563995 (Cpt2), Rn00571166
(Ucp2), Rn01460628 (Acox1), Rn00597339 (Hmgcs2),
Rn00569117 (Fas), Rn00580728 (Cd36), Rn00664587 (Fabp1),
Rn04219585 (Fabp4), Rn00585821 (Fatp1), Rn00561482 (Lpl),
Rn01423343 (Pltp), Rn00561474 (Lipc), Rn00563444 (Lipe),
Rn00562483 (ApoA1), Rn01499050 (ApoB), Rn01764530
(ApoC2), and Rn00560743 (ApoC3). All primer/probe
sequences for the genes studied were obtained from Applied
Biosystems. The MIQE guidelines for qPCR analyses were
used when selecting house-keeping genes [22, 23]. Three
house-keeping genes were tested: RT-CKFT-18s (18 S,
Eurogentec S.A., Seraing, Belgium), Rn03302271 gH (Rplp0,
Applied Biosystems), and Rn00821091 g1 (Rplp4, Applied
Biosystems). The house-keeping gene Rplp4 was found to be
the best using NormFinder [24] and was used to normalize
the expression value of each gene in all samples.
2.5. Statistical Analyses. All measurements except the gene
expression data were log-transformed and presented as
geometric means with their geometric standard deviations
(gSD). Gene expression data was normalized against the
control group (placebo) and presented as mean (SD) relative
to the control group. The groups were compared by a one-
way ANOVA, and the proportion of variance explained by
the experimental groups was assessed by calculating the
𝜂2. The assumption of equal variance was assessed with
Levene’s test and visually by plotting the residuals. Within-
group normality was assessed visually by Q-Q plots of the
residuals. Planned comparisons towards the control group
were performed for the two intervention groups, and p-
values were extracted from the regression model. Stan-
dardized mean difference (SMD; 95% confidence interval)
were calculated and plotted to illustrate the differences from
the control group. The p-values were adjusted using the
method of Benjamini and Hochberg [25] to control the false
discovery rate. The raw individual values were plotted with
overlaying box plots. The data file was processed in IBM
SPSS Statistics for Windows, version 23 (IBM Corporation,
Armonk, NY, USA), and statistics were performed in R
version 3.5.1 (https://www.R-project.org/), and the packages
within the tidyverse (dplyr, broom, purr,magrittr, and rlang)
and forestplot. P-values <0.05 were considered as statistically
significant.
3. Results
3.1. Weights and Lipid Related Parameters. Details on weight
measurements and lipid related parameters are illustrated in
Figure 1. At study start geometric mean (gSD) weight of the
animals was 247 (1.04) gram and during 12 days they gained
44.0 (1.22) gram. Neither baseline weights nor weight gain
significantly differed between treatment groups. Of interest,
the weights of the epididymal adipose tissue did not differ
between groups treated with agonists, compared to control
after 12 days intervention.
Treatment with WY-14,643 was associated with higher
liver weight and liver index (SMD = 6.4 and 10.3), lower
plasma total and HDL cholesterol (SMD = -5.2 and -4.5),
triglycerides (TAG; SMD= -1.5), phospholipids (SMD= -3.6),
and free cholesterol (SMD = -2.1), compared with control.
Furthermore, animals receiving the PPAR𝛼 agonist had lower
plasma levels of the carnitine precursor butyrobetaine (SMD
= -7.6), as well as carnitine (SMD = -1.6) and all measured
acylcarnitines (SMD = -4.1 - -1.9).
In liver, PPAR𝛼 activation was associated with lower total
cholesterol (SMD = -2.0) and higher phospholipids (SMD =
2.0). 𝛽-oxidation was higher (SMD = 4.8), while the ability
of inhibition by malonyl-CoA was substantially reduced
(SMD = -2.9).The activities of carnitine palmitoyltransferase
II (CPTII) (SMD = 5.4), fatty acyl-CoA oxidase (ACOX;
SMD = 21.3), and 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) synthase (SMD = 3.7) were all higher following
treatment with WY-14,643.
Free cardiac FAs were lower following PPAR𝛼 activation,
compared with control (SMD = -1.4).
Treatment with rosiglitazone was associated with a lower
liver index (SMD= -1.8), lower plasmaTAG (SMD= -2.6) and
phospholipids (SMD = -1.7), higher plasma butyrobetaine
(SMD = 2.2), and higher hepatic phospholipids (SMD = 1.3).
Supplemental Figure 1 illustrates the raw values of each
measured parameter from Figure 1.
Feed intake was estimated throughout the study, and
the rats who received the PPAR𝛾 agonist had a significantly
higher intake of chow compared with control (P<0.001).
However, there was no statistically significant impact on
weight gain or feed efficiency (weight gain per feed intake (g))
in either of the groups.
3.2. Fatty Acid Composition in Liver and Heart. Overall,
rats treated with the PPAR𝛼 agonist had higher hepatic
SFA (SMD = 2.5) and MUFA (SMD = 2.6) and lower n-6
(SMD = -1.8) and n-3 (SMD = -4.8) PUFAs, compared to
control (Figure 2). Along the MUFA pathway there was
a downstream increase towards a final higher mead acid
(C20:3n-9; SMD = 9.3). PPAR𝛼 activation was associated
with lower hepatic content of the essential PUFAs linoleic
(C18:2n-6) and 𝛼-linolenic (C18:3n-3) acids (SMD = -6.6
and -7.6), but with higher arachidonic acid (C20:4n-6; SMD
= 1.5) and lower levels of the most downstream n-3 PUFAs
(C20-22; SMD = -6.8, -5.8, and -3.2). Altogether, this was
in line with a lower PUFA n-3/n-6 ratio (SMD = -3.3)
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Figure 1: Weights and lipid related parameters in Wistar rats during treatment with PPAR agonists for 12 days. Values are geometric mean
(gSD). Red bars correspond to PPAR𝛼 vs control and blue bars to PPAR𝛾 vs control.Measurements of variables are in plasma, unless otherwise
stated. ACOX, fatty acyl-CoA oxidase; ANOVA, analysis of variance; CPTII, carnitine palmitoyltransferase II; EPI, epididymal fat; HDL,
high density lipoprotein; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A synthase; LDL, low density lipoprotein; PPAR, peroxisome
proliferator-activated receptor.
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Figure 2: Hepatic fatty acid composition (wt%) in Wistar rats after treatment with PPAR agonists for 12 days. Values are geometric mean
(gSD). Red bars correspond to PPAR𝛼 vs control and blue bars to PPAR𝛾 vs control. ANOVA, analysis of variance; MUFA, monounsaturated
fatty acids; PPAR, peroxisome proliferator-activated receptor; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids. D5 desaturase
index (n-6) = C20:4n-6 / C20:3n-6 (an indirect index of Δ5 desaturase activity based on n-6 PUFA). D5 desaturase index (n-3) = C20:5n-3 /
C20:4n-3 (an indirect index ofΔ5 desaturase activity based on n-3 PUFA). D6 desaturase index (n-6) = C18:3n-6 / C18:2n-6 (an indirect index
of Δ6 desaturase activity based on n-6 PUFA). D6 desaturase index (n-3) = C18:4n-3 / C18:3n-3 (an indirect index of Δ6 desaturase activity
based on n-3 PUFA). D9 desaturase index (C16) = C16:1n-7 / C16:0 (an indirect index ofΔ9 desaturase activity based on C16 SFA/MUFA). D9
desaturase index (C18) = C18:1n-9 / C18:0 (an indirect index of Δ9 desaturase activity based on C18 SFA/MUFA). Anti-inflammatory index =
((C22:6n-3 + C22:5n-3 + C20:3n-6 + C20:5n-3) / C20:4n-6)∗100.
treatment. Furthermore, there was an overall lower estimated
Δ5 desaturase activity and a higher estimated Δ6 desaturase
activity in animals treated with the PPAR𝛼 agonist. The Δ9
desaturase index based on C16 was lower (SMD = -3.1), while
that based on C18 was higher (SMD = 4.1).
The strongest effects on hepatic FA composition fol-
lowing treatment with rosiglitazone were higher contents
of mead acid (C20:3n-9; SMD = 3.6) and eicosapentaenoic
acid (C20:5n-3; SMD = 2.7) compared to control, the last
mentioned also illustrated by the increase in estimated Δ5
desaturase activity along the n-3 pathway (SMD = 1.9).
Supplemental Figure 2 illustrates the raw values of each
measured parameter from Figure 2. FA composition in
plasma was very similar to that observed in hepatic tissue,
with few exceptions (Supplemental Figure 3).
Certain changes were also seen in heart tissue following
treatment with the PPAR agonists (Figure 3). Administra-
tion of WY-14,643 was associated with higher mead acid
6 PPAR Research
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Figure 3: Cardiac fatty acid composition (wt%) in Wistar rats after treatment with PPAR agonists for 12 days. Values are geometric mean
(gSD). Red bars correspond to PPAR𝛼 vs control and blue bars to PPAR𝛾 vs control. ANOVA, analysis of variance; MUFA, monounsaturated
fatty acids; PPAR, peroxisome proliferator-activated receptor; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids. D5 desaturase
index (n-6) = C20:4n-6 / C20:3n-6 (an indirect index of Δ5 desaturase activity based on n-6 PUFA). D5 desaturase index (n-3) = C20:5n-3 /
C20:4n-3 (an indirect index ofΔ5 desaturase activity based on n-3 PUFA). D6 desaturase index (n-6) = C18:3n-6 / C18:2n-6 (an indirect index
of Δ6 desaturase activity based on n-6 PUFA). D6 desaturase index (n-3) = C18:4n-3 / C18:3n-3 (an indirect index of Δ6 desaturase activity
based on n-3 PUFA). D9 desaturase index (C16) = C16:1n-7 / C16:0 (an indirect index ofΔ9 desaturase activity based on C16 SFA/MUFA). D9
desaturase index (C18) = C18:1n-9 / C18:0 (an indirect index of Δ9 desaturase activity based on C18 SFA/MUFA). Anti-inflammatory index =
((C22:6n-3 + C22:5n-3 + C20:3n-6 + C20:5n-3) / C20:4n-6)∗100.
(C20:3n-9; SMD = 4.8), lower linoleic acid (C18:2n-6; SMD
= -1.5), and higher arachidonic acid (C20:4n-6; SMD = 2.2).
Treatment with rosiglitazone was associated with lower total
cardiac FAs (SMD = -1.5) and SFA (SMD = -1.7) and higher
cardiac n-6 PUFA (SMD = 1.7) due to higher linoleic acid
(C18:2n-6; SMD = 2.7), compared to control.
Supplemental Figure 4 illustrates the raw values of each
measured parameter from Figure 3.
3.3. Gene Expression in Liver and Epididymal Adipose Tissue.
Several established PPAR target genes were affected in liver
after treatment with WY-14,643 (Figure 4). Fatty acyl-CoA
oxidase 1 (Acox1) is the rate-limiting enzyme of peroxisomal
𝛽-oxidation, whereas carnitine palmitoyltransferases 1a and
2 (Cpt1a and Cpt2) are involved in the transfer of FAs into
the mitochondria. Under certain metabolic circumstances





























































































































Figure 4: Hepatic gene expression in Wistar rats after treatment with PPAR agonists for 12 days, normalized towards the control group. Red
bars correspond to PPAR𝛼 vs control and blue bars to PPAR𝛾 vs control. Acox1, fatty acyl-CoAoxidase 1; ANOVA, analysis of variance; ApoA1,
apolipoprotein A1; ApoB, apolipoprotein B; ApoC2, apolipoprotein C2; ApoC3, apolipoprotein C3; Cd36, cluster of differentiation 36; Cpt1a,
carnitine palmitoyltransferase 1a; Cpt2, carnitine palmitoyltransferase 2; Fabp1, fatty acid binding protein 1; Fas, fatty acid synthase; Fatp1,
fatty acid transport protein 1; Hmgcs2, 3-hydroxy-3-methylglutaryl-CoA synthase 2; Lipc, hepatic lipase C; Lpl, lipoprotein lipase; Pgc1𝛼,
peroxisome proliferator-activated receptor › coactivator 1𝛼; Pltp, phospholipid transfer protein; Ppar𝛼, peroxisome proliferator-activated
receptor 𝛼; Ppar›, peroxisome proliferator-activated receptor ›; TNFa, tumor necrosis factor alpha; Ucp2, uncoupling protein 2.
3-hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2) into
ketone bodies. Transport proteins important for FAs include
Cluster of differentiation 36 (Cd36), fatty acid binding protein
1 (Fabp1), and fatty acid transport protein 1 (Fatp1). Lipopro-
tein lipase (Lpl) is activated by Apolipoprotein C2 (ApoC2)
and contributes to increased lipolysis of TAG. Whereas
PPAR𝛼, Cpt1a, Cpt2, Acox1, Hmgcs2, Cd36, Fabp1, Fatp1, and
Lpl were upregulated (SMD = 1.7 – 9.5), Pltp, Lipc, ApoA1,
ApoC2, and ApoC3 (SMD = -6.6 - -2.1) were downregulated,
compared with control. Only few hepatic genes were appre-
ciably affected by treatment with rosiglitazone. These were
PPAR𝛼, Pgc1𝛼, Cpt1a, and Cd36, which were all upregulated
(SMD = 1.4 – 1.5).
Supplemental Figure 5 illustrates the raw values of gene
expression relative to control from Figure 4.
In epididymal adipose tissue, no genes were clearly
affected by PPAR𝛼 administration, whereas Cpt2, Acox1,
Fabp4, and Fatp1 were upregulated by PPAR𝛾 administration
(SMD = 1.2 - 2.6) (Figure 5).
Supplemental Figure 6 illustrates the raw values of gene
expression relative to control from Figure 5.
4. Discussion
Overall, in the current short-term study of PPAR𝛼 and
PPAR𝛾 activation, we present a comprehensive report with
specific effects on circulating lipids, FA composition in liver,
heart, and plasma and expression of known PPAR target
genes in liver and adipose tissue. PPAR𝛼 activation was
obtained by treatment with WY-14,643, while PPAR𝛾 acti-
vation was obtained by treatment with rosiglitazone. PPAR𝛼
activation was associated with lower plasma total cholesterol,
HDL cholesterol, TAG, and phospholipids, higher hepatic





































































































Figure 5: Epididymal adipose tissue gene expression in Wistar rats after treatment with PPAR agonists for 12 days, normalized towards the
control group. Red bars correspond to PPAR𝛼 vs control and blue bars to PPAR𝛾 vs control. Acox1, fatty acyl-CoA oxidase 1; ANOVA, analysis
of variance; Cd36, cluster of differentiation 36; Cpt1a, carnitine palmitoyltransferase 1a; Cpt2, carnitine palmitoyltransferase 2; Fabp4, fatty
acid binding protein 4; Fas, fatty acid synthase; Fatp1, fatty acid transport protein 1; Hmgcs2, 3-hydroxy-3-methylglutaryl-CoA synthase 2;
Lipe, hormone sensitive lipase E; Lpl, lipoprotein lipase; Pgc1𝛼, peroxisome proliferator-activated receptor › coactivator 1𝛼; Pltp, phospholipid
transfer protein; Ppar𝛼, peroxisome proliferator-activated receptor 𝛼; Ppar›, peroxisome proliferator-activated receptor ›; TNFa, tumor
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Figure 6: A summary showing main effects of PPAR𝛼 and PPAR𝛾 activation as observed in the current study in the circulation, liver, heart,
and adipose tissue as indicated. PPAR𝛼 effects are shown in red, while PPAR𝛾 effects are shown in blue.
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PUFA, and higher cardiac arachidonic acid. PPAR𝛾 activa-
tion was associated with lower plasma TAG and phospho-
lipids, lower cardiac total FAs and SFA, and higher cardiac
n-6 PUFA. A summary of characteristic effects of PPAR𝛼 and
PPAR𝛾 activation in the circulation, as well as in liver, heart,
and adipose tissue is illustrated in Figure 6.
The effects of PPAR𝛼 agonist stimulation on hepatic lipid
metabolism in rodents are well-documented and include
induced FA uptake, 𝛽-oxidation, ketogenesis, and TAG clear-
ance [26]. Similar effects are observed in heart and skeletal
muscle, but to a much lesser degree due to the tissue-specific
expression pattern of PPAR𝛼 [27]. Thus, liver plays a major
role in PPAR𝛼-induced plasma lipid lowering. Moreover,
hepatic peroxisome proliferation, related to increased liver
weight, is a well-known effect in response to PPAR stimu-
lation in rodents [28]. In addition, activation of PPAR𝛼 will
result in body weight loss after prolonged treatment [29, 30].
PPAR𝛾 agonists, in contrast, have more prominent effects on
adipose tissue. Rosiglitazone has been shown to stimulate
the lipid storage capacity of adipose tissue, increase lipid
uptake, and efficiently reduce plasma glucose levels [31–33].
Activation of PPAR𝛾 has been postulated to regulate the
expression of adipose triglyceride lipase (ATGL), which has
an important role in lipid metabolism [34]. Furthermore,
rosiglitazone treatment has been associated with increased
ATGL expression in WAT and BAT of lean and obese mice
[34].
Although the roles of PPAR𝛼 and -𝛾 on lipid metabolism
in rodents have been described previously, few studies have
performed a comprehensive comparison of PPAR𝛼 and
PPAR𝛾 agonists on lipids, FA composition, and gene expres-
sion in major organs involved in lipid turnover. Findings
in animals treated with the PPAR𝛼 agonist indicated an
increased hepatic 𝛽-oxidation and ketogenesis compared to
rats treated with vehicle. An enhanced FA transport and
uptake is supported by an increased hepatic expression of
Cd36, Fabp1, and Fatp1 [26]. Interestingly, gene expression in
adipose tissue was not influenced by two weeks ofWY-14,643
treatment. Rosiglitazone treatment led to higher expression
of hepatic Pgc1a, Cpt1a, and Cd36, although not to an extent
comparable with the effect of WY-14,643 treatment. More-
over, pharmacological activation of PPAR𝛾 was associated
with higher expression of adipose Cpt2, Acox1, Fabp4, and
Fatp1 compared with control. As there was a strong plasma
TAG reducing effect after PPAR𝛾 activation, our results
indicate that PPAR𝛾-induced lipid transport and catabolism
in adipose tissue may contribute to the reduction in plasma
TAG levels. Similarly, short-term PPAR𝛾 activation, through
rosiglitazone therapy, showed reduced plasma TAG and
NEFAs in Wistar rats [35]. Moreover, Harrington et al.
showed that a PPAR𝛾 agonist GW7845 reduced plasma TAG
levels in AKR/J mice treated for four weeks, which did not
relate to increased in vitro hepatic FA oxidation [36]. PPAR𝛾
activation has previously shown to reduce plasma TAG in
rats through adipose tissue-specific increase in LPL activity
as well as increased gene expression of FA transport proteins,
and this process requires mTOR activity [37, 38]. Increased
LPL activity has been associated with enhanced lipolytic
activity, which in turn is associated with TAG clearance [39].
In the current study, gene expression patterns demonstrated
minor decrease in Lpl in adipose tissue following treatment
with both PPAR agonists. On the contrary, there was an
enhanced activity of genes associated with 𝛽-oxidation in
adipose tissue following rosiglitazone treatment.
Several studies have shown that PPAR𝛾 agonists increase
feed intake and body weight and reduce plasma glucose and
insulin levels, while the PPAR𝛼 agonists reduce body weight
[36].Wedidnot observe any statistically significant difference
in weight gain between the treatment groups, despite an
increase in feed intake among PPAR𝛾 supplemented rats.
Moreover, glucose levels were unchanged. This could be due
to the relatively short treatment period, as the PPAR𝛾 group
did gain more weight in absolute terms.
Plasma carnitine metabolites were in general reduced
after treatment with WY-14,643, but there were minor effects
after treatment with rosiglitazone. Treatment of rats with a
PPAR𝛼 specific agonist [40] and a pan PPAR agonist with
main affinity for PPAR𝛼 [41] did also demonstrate reduced
plasma acylcarnitine levels and increased expression of the
Bbox1 gene involved in production of the carnitine precursor
butyrobetaine. Carnitine is essential for the transport of
medium and long fatty acyl chains in and out of the mito-
chondrion, and plasma levels may reflect intracellular levels.
Thus, the reduction in plasma carnitine and its precursor
butyrobetaine by PPAR𝛼may have been due to an increased
utilization of carnitine for FA transport, while the reduction
in acylcarnitines could be linked to the increased 𝛽-oxidation
and ketogenesis, lowering the levels of intermediate and
end-products of 𝛽-oxidation. In line with this, acylcar-
nitines have been proposed as sensors of mitochondrial FA
oxidation [42], and high levels of palmitoylcarnitine and
octanoylcarnitine are linked to poor prognosis in patients
with cardiovascular disease [13, 43]. Our results indicate that
PPAR𝛾 has little influence on plasma acylcarnitines, despite
the increased expression of genes involved in adipose tissue
𝛽-oxidation.
Hepatic peroxisome proliferation leads to induced
peroxisomal- and as an indirect consequence also
mitochondrial 𝛽-oxidation [44]. This strong effect on
liver exerted by PPAR𝛼 may be reflected by its impact on
hepatic FA composition. Although peroxisome proliferation
does not occur in a similar manner in humans as in
rodents, changes in FA composition in relation to 𝛽-
oxidation rate can provide clues in the search for possible
FA markers indicating PPAR activation under certain
circumstances also in humans. It is conceivable that an
increased peroxisomal catabolism of very long-chain FAs
and subsequent oxidation in the mitochondria may induce
shifts in FA composition. A study in ageing rats indicated
that extent of peroxisomal 𝛽-oxidation affected brain
FA composition [44]. Moreover, WY-14643 affected FA
composition of myocardial phospholipids [45]. We have
previously studied long-term PPAR𝛼 activation in rats,
resulting in elevated cardiac levels, as opposed to lower
hepatic levels of n-3 PUFAs [14]. These tissue-specific
differences are similar to those observed in the current
short-term study, including lower hepatic n-3 PUFA
and a tendency of elevated cardiac n-3 PUFA levels. The
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lower hepatic level of n-3 PUFAs in animals treated with
PPAR𝛼 agonist may be a consequence of the increased
hepatic 𝛽-oxidation, particularly since the long-chain n-3
PUFAs are preferred FA substrates for 𝛽-oxidation [46].
Interestingly, in both studies, mead acid was elevated in liver
and heart, a PPAR mechanism which may be linked with
an essential FA deficiency [47]. It is not straight-forward
to interpret exactly which mechanisms can be related to
levels of SFAs and MUFAs, as these are more dependent
on endogenous conversion compared to those of the PUFA
subtype which are more directly related to the dietary intake
[48].
In the current study, focus has been on PPAR𝛼- and 𝛾
specific effects in metabolic active tissues, including liver,
heart, and adipose tissue. Altogether, induced 𝛽-oxidation
and enzymatic activity of PPAR𝛼 target proteins were sup-
portive of well-known PPAR𝛼 specific effects in liver. Short-
term treatment with rosiglitazone, a PPAR𝛾 specific synthetic
agonist, reduced plasma TAG in male Wistar rats, which
may relate to adipose tissue-specific effects on mitochon-
drial function and lipid uptake. Moreover, PPAR𝛾 activity
seemed to affect 𝛽-oxidation in adipose tissue. Altogether,
the current study demonstrates that PPAR𝛼 and PPAR𝛾
specific ligands will influence lipids, gene expression, as well
as FA composition in a tissue-specificmanner.These findings
are important for future studies on dietary components,
when investigating which traits can be associated with PPAR
related effects. It is also interesting to reveal PPAR effects
on carnitine metabolites, which are potential biomarkers in
human disease [49].
5. Conclusions
Short-term treatment with synthetic PPAR𝛼 and PPAR𝛾
agonists induced changes in circulating lipids and FA compo-
sition in liver and heart,modifyingmitochondrial function in
a tissue-specific manner. Interestingly, we observed TAG and
phospholipid lowering effects in plasma after treatment with
both agonists. The ultimate future aim is to gain knowledge
on how these parameters may be affected not only by
activation through specific PPAR agonists, but also by dietary
FAs as well as other dietary and lifestyle related factors. More
knowledge regarding PPAR actionmay be a part of the puzzle
when laying the foundation for patient-specific dietary and
medical prevention and treatment of metabolic diseases like
obesity, diabetes, and cardiovascular diseases.
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nitine and acylcarnitines in plasma by high-performance liquid
chromatography/electrospray ionization ion trap tandem mass
spectrometry,” Rapid Communications in Mass Spectrometry,
vol. 18, no. 11, pp. 1233–1238, 2004.
[12] B. Bjørndal, L. Burri, H. Wergedahl, A. Svardal, P. Bohov,
and R. K. Berge, “Dietary supplementation of herring roe and
milt enhances hepatic fatty acid catabolism in female mice
transgenic for hTNF𝛼,” European Journal of Nutrition, vol. 51,
no. 6, pp. 741–753, 2012.
[13] E. Strand, E. R. Pedersen, G. F. T. Svingen et al., “Serum acylcar-
nitines and risk of cardiovascular death and acute myocardial
infarction in patients with stable angina pectoris,” Journal of the
American Heart Association, vol. 6, no. 2, 2017.
[14] E. Strand, B. Bjorndal, O. Nygard et al., “Long-term treatment
with the pan-PPAR agonist tetradecylthioacetic acid or fish oil
is associated with increased cardiac content of n-3 fatty acids in
rat,” Lipids in Health and Disease, vol. 11, article 82, 2012.
[15] S. R. Chavali, W. W. Zhong, T. Utsunomiya, and R. A. Forse,
“Decreased production of interleukin-1-beta, prostaglandin-E2
and thromboxane-B2, and elevated levels of interleukin-6 and
-10 are associated with increased survival during endotoxic
shock in mice consuming diets enriched with sesame seed oil
supplemented with Quil-A saponin,” International Archives of
Allergy and Immunology, vol. 114, no. 2, pp. 153–160, 1997.
[16] R. K. Berge and T. Flatmark, “Osmundsen H: Enhancement
of long-chain acyl-CoA hydrolase activity in peroxisomes
and mitochondria of rat liver by peroxisomal proliferators,”
European Journal of Biochemistry, vol. 141, no. 3, pp. 637–644,
1984.
[17] N. Willumsen, S. Hexeberg, J. Skorve, M. Lundquist, and R. K.
Berge, “Docosahexaenoic acid shows no triglyceride-lowering
effects but increases the peroxisomal fatty acid oxidation in liver
of rats,” Journal of Lipid Research, vol. 34, no. 1, pp. 13–22, 1993.
[18] L. Madsen, L. Froyland, E. Dyroy, K. Helland, and R. K. Berge,
“Docosahexaenoic and eicosapentaenoic acids are differently
metabolized in rat liver during mitochondria and peroxisome
proliferation,” 
e Journal of Lipid Research, vol. 39, no. 3, pp.
583–593, 1998.
[19] R. K. Berge, T. Flatmark, and E. N. Christiansen, “Effect of a
high-fat diet with partially hydrogenated fish oil on long-chain
fatty acid metabolizing enzymes in subcellular fractions of rat
liver,”Archives of Biochemistry and Biophysics, vol. 252, no. 1, pp.
269–276, 1987.
[20] R. K. Berge, A. Nilsson, and A.-M.Husøy, “Rapid stimulation of
liver palmitoyl-CoA synthetase, carnitine palmitoyltransferase
and glycerophosphate acyltransferase compared to peroxisomal
𝛽-oxidation and palmitoyl-CoA hydrolase in rats fed high-fat
diets,” Biochimica et Biophysica Acta (BBA) - Lipids and Lipid
Metabolism, vol. 960, no. 3, pp. 417–426, 1988.
[21] K. D. Clinkenbeard,W. D. Reed, R. A. Mooney, andM. D. Lane,
“Intracellular localization of the 3-hydroxy-3-methylglutaryl
coenzme A cycle enzymes in liver. Separate cytoplasmic and
mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A gen-
erating systems for cholesterogenesis and ketogenesis.,” 
e
Journal of Biological Chemistry, vol. 250, no. 8, pp. 3108–3116,
1975.
[22] S. A. Bustin, V. Benes, J. A. Garson et al., “TheMIQE guidelines:
minimum information for publication of quantitative real-time
PCRexperiments,”Clinical Chemistry, vol. 55, no. 4, pp. 611–622,
2009.
[23] T. Nolan, R. E. Hands, and S. A. Bustin, “Quantification of
mRNA using real-time RT-PCR,” Nature Protocols, vol. 1, no. 3,
pp. 1559–1582, 2006.
[24] C. L. Andersen, J. L. Jensen, and T. F. Ørntoft, “Normalization of
real-time quantitative reverse transcription-PCR data: a model-
based variance estimation approach to identify genes suited for
normalization, applied to bladder and colon cancer data sets,”
Cancer Research, vol. 64, no. 15, pp. 5245–5250, 2004.
[25] Y. Benjamini and Y. Hochberg, “Controlling the false discovery
rate: a practical and powerful approach to multiple testing,”
Journal of the Royal Statistical Society B: Methodological, vol. 57,
no. 1, pp. 289–300, 1995.
[26] L. Burri, G. H. Thoresen, and R. K. Berge, “The role of PPAR
activation in liver and muscle,” PPAR Research, 2010.
[27] O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli,
“Differential expression of peroxisome proliferator-activated
receptors (PPARs): tissue distribution of PPAR-𝛼, -𝛽, and -𝛾 in
the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.
[28] S. Dzhekova-Stojkova, J. Bogdanska, and Z. Stojkova, “Perox-
isome proliferators: their biological and toxicological effects,”
Clinical Chemistry and Laboratory Medicine, vol. 39, no. 6, pp.
468–474, 2001.
[29] M. Perreault, S. Will, D. Panza et al., “Modulation of nutri-
ent sensing nuclear hormone receptors promotes weight loss
through appetite suppression in mice,” Diabetes, Obesity and
Metabolism, vol. 12, no. 3, pp. 234–245, 2010.
[30] T. L. Rachid, A. Penna-de-Carvalho, I. Bringhenti,M. B. Aguila,
C. A.Mandarim-de-Lacerda, and V. Souza-Mello, “PPAR-alpha
agonist elicitsmetabolically active brown adipocytes andweight
loss in diet-induced obese mice,” Cell Biochemistry & Function,
vol. 33, no. 4, pp. 249–256, 2015.
[31] W. T. Festuccia, P.-G. Blanchard, V. Turcotte et al., “Depot-
specific effects of the PPARgamma agonist rosiglitazone on
adipose tissue glucose uptake and metabolism,” Journal of Lipid
Research, vol. 50, no. 6, pp. 1185–1194, 2009.
[32] M. Laplante, H. Sell, K. L. MacNaul, D. Richard, J. P. Berger, and
Y. Deshaies, “PPAR-gamma activation mediates adipose depot-
specific effects on gene expression and lipoprotein lipase activ-
ity: mechanisms for modulation of postprandial lipemia and
differential adipose accretion,” Diabetes, vol. 52, no. 2, pp. 291–
299, 2003, http://www.ncbi.nlm.nih.gov/pubmed/12540599.
12 PPAR Research
[33] M. Laplante,W. T. Festuccia, G. Soucy et al., “Mechanisms of the
depot specificity of peroxisome proliferator-activated receptor 𝛾
action on adipose tissue metabolism,” Diabetes, vol. 55, no. 10,
pp. 2771–2778, 2006.
[34] E. E. Kershaw, M. Schupp, H.-P. Guan, N. P. Gardner, M. A.
Lazar, and J. S. Flier, “PPAR𝛾 regulates adipose triglyceride
lipase in adipocytes in vitro and in vivo,” American Journal of
Physiology-Endocrinology and Metabolism, vol. 293, no. 6, pp.
E1736–E1745, 2007.
[35] M. M. Naderali, I. Itua, A. R. Abubakari, and E. K. Nader-
ali, “Short-Term therapy with rosiglitazone, a PPAR-gamma
Agonist, improves metabolic profile and vascular function in
nonobese lean wistar rats,” ISRN Pharmacol, vol. 2012, Article
ID 130347, 2012.
[36] W. W. Harrington, C. S. Britt, J. G. Wilson et al., “The effect
of PPAR𝛼, PPAR𝛿, PPAR𝛾, and PPARpan agonists on body
weight, body mass, and serum lipid profiles in diet-induced
obese AKR/J mice,” PPAR Research, vol. 2007, Article ID 97125,
13 pages, 2007.
[37] M. Laplante, W. T. Festuccia, G. Soucy et al., “Tissue-
specific postprandial clearance is the major determinant of
PPARgamma-induced triglyceride lowering in the rat,” Amer-
ican Journal of Physiology-Regulatory, Integrative and Compara-
tive Physiology, vol. 296, no. 1, pp. R57–R66, 2009.
[38] P.-G. Blanchard, W. T. Festuccia, V. P. Houde et al., “Major
involvement ofmTOR in the PPARgamma-induced stimulation
of adipose tissue lipid uptake and fat accretion,” Journal of Lipid
Research, vol. 53, no. 6, pp. 1117–1125, 2012.
[39] J. Auwerx, K. Schoonjans, J.-C. Fruchart, and B. Staels, “Tran-
scriptional control of triglyceridemetabolism: Fibrates and fatty
acids change the expression of the LPL and apo C-III genes by
activating the nuclear receptor PPAR,” Atherosclerosis, vol. 124,
pp. S29–S37, 1996.
[40] K. Sheikh, G. Camejo, B. Lanne, T. Halvarsson, M. R. Lan-
dergren, and N. D. Oakes, “Beyond lipids, pharmacologi-
cal PPARalpha activation has important effects on amino
acid metabolism as studied in the rat,” American Journal of
Physiology-Endocrinology and Metabolism, vol. 292, no. 4, pp.
E1157–E1165, 2007.
[41] N. F. Vigerust, D. Cacabelos, L. Burri et al., “Fish oil and 3-
thia fatty acid have additive effects on lipid metabolism but
antagonistic effects on oxidative damage when fed to rats for
50 weeks,” 
e Journal of Nutritional Biochemistry, vol. 23, no.
11, pp. 1384–1393, 2012.
[42] A. Ribel-Madsen, R. Ribel-Madsen, C. Brøns, C. B. Newgard,
A. A. Vaag, and L. I. Hellgren, “Plasma acylcarnitine profiling
indicates increased fatty acid oxidation relative to tricarboxylic
acid cycle capacity in young, healthy low birth weight men,”
Physiological Reports, vol. 4, no. 19, 2016.
[43] T. Ueland, A. Svardal, E. Øie et al., “Disturbed carnitine
regulation in chronic heart failure - Increased plasma levels
of palmitoyl-carnitine are associated with poor prognosis,”
International Journal of Cardiology, vol. 167, no. 5, pp. 1892–1899,
2013.
[44] L. Yang, Y. Zhang, S. Wang, W. Zhang, and R. Shi, “Decreased
liver peroxisomal𝛽-oxidation accompanied by changes in brain
fatty acid composition in aged rats,” Neurological Sciences, vol.
35, no. 2, pp. 289–293, 2014.
[45] M. Baranowski, A. Blachnio-Zabielska, and J. Gorski, “Perox-
isome proliferator-activated receptor alpha activation induces
unfavourable changes in fatty acid composition of myocardial
phospholipids,” Journal of Physiology and Pharmacology, vol. 60,
no. 2, pp. 13–20, 2009.
[46] J. P. DeLany, M. M. Windhauser, C. M. Champagne, and G. A.
Bray, “Differential oxidation of individual dietary fatty acids in
humans,” American Journal of Clinical Nutrition, vol. 72, no. 4,
pp. 905–911, 2000.
[47] I. Ichi, N. Kono, Y. Arita et al., “Identification of genes and
pathways involved in the synthesis of Mead acid (20:3n - 9),
an indicator of essential fatty acid deficiency,” Biochimica et
Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids,
vol. 1841, no. 1, pp. 204–213, 2014.
[48] L. Arab, “Biomarkers of Fat and Fatty Acid Intake,” Journal of
Nutrition, vol. 133, no. 3, pp. 925S–932S, 2003.
[49] J. L. Flanagan, P. A. Simmons, J. Vehige, M. D. Willcox, and Q.
Garrett, “Role of carnitine in disease,” Journal of Nutrition and
Metabolism, vol. 7, article 30, 2010.
